MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Proceeds from medtronicterm loan$20,000K Proceeds from the royaltypurchase agreement$15,000K Proceeds fromat-the-market offering, net of...$5,855K Proceeds from exercise ofstock options$34K (-62.64%↓ Y/Y)Net cash provided by(used in) financing...$40,273K (5662.57%↑ Y/Y)Canceled cashflow$616K Net decrease in cashand cash...-$14,218K (-304.84%↓ Y/Y)Canceled cashflow$40,273K Stock-based compensation$5,356K (-13.82%↓ Y/Y)Non-cash interestexpense on liability...$3,111K Accrued interestexpense on liability...$442K Non-cash lease expense$325K (9.43%↑ Y/Y)Depreciation andamortization$186K (13.41%↑ Y/Y)Amortization of deferredfinancing fees$129K (40.22%↑ Y/Y)Inventory-$60K (-645.45%↓ Y/Y)Accounts receivable-$44K (-388.89%↓ Y/Y)Prepaid expenses andother assets-$14K (90.54%↑ Y/Y)Sales of marketablesecurities$38,791K (19.71%↑ Y/Y)Sale of strategicinvestments$4,781K Restricted stock unitswithheld for tax$616K (-24.42%↓ Y/Y)Net cash used inoperating activities-$41,500K (-29.11%↓ Y/Y)Canceled cashflow$9,667K Net cash (used in)provided by investing...-$12,991K (-144.25%↓ Y/Y)Totalrevenue-Product$198K Canceled cashflow$43,572K Net loss-$44,446K (-16.60%↓ Y/Y)Canceled cashflow$198K Accounts payable,accrued expenses and...-$3,311K (-472.86%↓ Y/Y)Gain on sale ofstrategic investments$2,286K Accretion and interestrelated to marketable...$476K (195.65%↑ Y/Y)Operating leaseliabilities - current and...-$359K (-34.46%↓ Y/Y)Change in the fair valueof derivative...$289K Purchases of marketablesecurities$56,125K (1834.01%↑ Y/Y)Purchases of property andequipment$438K (200.00%↑ Y/Y)Personnel and consultingcosts$17,611K Development costs-ClinicalDevelopment Costs$8,534K Development costs-NonClinical Development...$7,429K Stock-based compensation$5,356K (-13.82%↓ Y/Y)Other segmentexpenses$2,882K Interest expense(income), net-$2,589K Depreciation andamortization expense$186K Cost of productrevenues$57K
Cash Flow

Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed Holdings, Inc. (OBIO)

source: myfinsight.com